- Home
- HQI vs PBYI Comparison
HQI vs PBYI Comparison
Compare HQI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HQI | PBYI |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | 75000 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.8M | 364.9M |
| IPO Year | 2008 | 2011 |
Fundamental Metrics
Financial Performance| Metric | HQI | PBYI |
|---|---|---|
| Price | $12.77 | $8.26 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | 15.2K | ★ 285.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $30,640,000.00 | $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.46 | N/A |
| P/E Ratio | $116.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $3.03 |
| 52 Week High | $14.54 | $8.41 |
Technical Indicators
Market Signals| Indicator | HQI | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 65.54 |
| Support Level | $11.95 | $6.41 |
| Resistance Level | $13.02 | $8.41 |
| Average True Range (ATR) | 0.84 | 0.35 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 33.77 | 89.66 |
Price Performance
Historical ComparisonAbout HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.